专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110172121A1 ALLOGENEIC STEM CELL BANK 审中-公开
标题翻译：全息干细胞库
公开(公告)号：US20110172121A1
公开(公告)日：2011-07-14
申请号：US12908143
申请日：2010-10-20
申请人： Robert Chow , Lawrence D. Petz , Rubio R. Punzalan , Denis O. Rodgerson
发明人： Robert Chow , Lawrence D. Petz , Rubio R. Punzalan , Denis O. Rodgerson
IPC分类号： C40B40/02
CPC分类号： A61K35/50 , A61K35/16 , A61K35/28 , G16H50/80
摘要： This invention provides methods for supplying a therapy for individuals exposed to radiation following a nuclear event, through the prospective establishment of an undesignated allogeneic stem cell bank with prospective HLA typing of healthy potential recipients.
摘要翻译：本发明提供了通过预期建立具有健康潜在接受者的预期HLA分型的未指定的同种异体干细胞库来为在核事件之后暴露于辐射的个体提供治疗的方法。

2. 发明申请

US20080227197A1 ALLOGENEIC STEM CELL BANK 审中-公开
标题翻译：全息干细胞库
公开(公告)号：US20080227197A1
公开(公告)日：2008-09-18
申请号：US12110850
申请日：2008-04-28
申请人： Robert Chow , Lawrence D. Petz , Rubio R. Punzalan , Denis O. Rodgerson
发明人： Robert Chow , Lawrence D. Petz , Rubio R. Punzalan , Denis O. Rodgerson
IPC分类号： C12N5/08
CPC分类号： A61K35/50 , A61K35/16 , A61K35/28 , G16H50/80
摘要： This invention provides methods for supplying a therapy for individuals exposed to radiation following a nuclear event, through the prospective establishment of an undesignated allogeneic stem cell bank with prospective HLA typing of healthy potential recipients.
摘要翻译：本发明提供了通过预期建立具有健康潜在接受者的预期HLA分型的未指定的同种异体干细胞库来为在核事件之后暴露于辐射的个体提供治疗的方法。

3. 发明授权

US5480777A Kinetic enzyme assay for determining the CO.sub.2 content of body fluids using PEP carboxylase with inhibitor 失效
标题翻译：动力学酶法测定使用PEP羧化酶与抑制剂的体液二氧化碳含量
公开(公告)号：US5480777A
公开(公告)日：1996-01-02
申请号：US375946
申请日：1995-01-20
申请人： Bryce A. Cunningham , George F. Johnson , Rubio R. Punzalan
发明人： Bryce A. Cunningham , George F. Johnson , Rubio R. Punzalan
IPC分类号： C12Q1/32 , C12Q1/48 , C12Q1/527 , C12N9/10 , C12N9/88
CPC分类号： C12Q1/48 , C12Q1/32 , C12Q1/527
摘要： An improved kinetic assay is provided for spectrophotometrically determining the dissolved carbon dioxide (CO.sub.2) content of a body fluid (e.g., blood, plasma or serum), wherein at about pH 8.0 the CO.sub.2 is present substantially as bicarbonate ion (HCO.sub.3.sup.-). The assay sample is first subjected to a coupled reaction mixture containing phosphoenolpyruvate (PEP) and phospho-enolpyruvate carboxylase (PEPC) which enzymatically catalyzes conversion of HCO.sub.3.sup.- to oxaloacetate (OA). The OA produced is subjected to a second coupled reaction mixture containing nicotinamide adenine dinucleotide (NADH) and malate dehydrogenase (MDH) which thereby reduces the OA to malate and oxidizes the NADH to AND.sup.+. The CO.sub.2 level in the body fluid sample may indirectly be determined by spectrophotometrically measuring the change in NADH concentration. According to the invention, an amount of an inhibitor is added to the reaction mixture which renders the reaction kinetics of the system essentially first order over the entire bicarbonate concentration range of interest. A useful inhibitor substantially satisfies a model represented by the monoexponential equationA.sub.t =(A.sub.o -A.sub..infin.)e.sup.-kt +A.sub..infin. [I]A sufficient quantity of the inhibitor is present to substantially cause the coupled reactions to follow the model equation [I] and yield a number which is within about .+-.200% of the noise level of the spectrophotometer used for the assay when each absorbance value is applied to the equation ##EQU1## Best results have been obtained through use of an inhibitor which provides an anion selected from the group consisting of ClO.sub.3.sup.-, ClO.sub.4.sup.-, SCN.sup.-, or I.sup.-.
摘要翻译：提供改进的动力学测定用于分光光度测定体液（例如血液，血浆或血清）的溶解二氧化碳（CO 2）含量，其中在约pH8.0时，CO 2基本上以碳酸氢根离子（HCO 3 - ）存在。首先对测定样品进行含有磷酸烯醇丙酮酸（PEP）和磷酸烯醇丙酮酸羧化酶（PEPC）的偶联反应混合物，其中酶促催化HCO3-转化为草酰乙酸（OA）。生成的OA经受含有烟酰胺腺嘌呤二核苷酸（NADH）和苹果酸脱氢酶（MDH）的第二偶联反应混合物，从而将OA还原为苹果酸，并将NADH氧化成为+。通过分光光度法测量体液样品中的二氧化碳水平可以间接测定NADH浓度的变化。根据本发明，将一定量的抑制剂加入到反应混合物中，使得系统的反应动力学在感兴趣的整个碳酸氢盐浓度范围内基本上是一级。有用的抑制剂基本上满足由单指数方程表示的模型At =（Ao-A INFINITY）e-kt + A INFINITY [I]存在足够量的抑制剂以基本上使偶联反应遵循模型方程[I ]，并且当将每个吸光度值应用于方程式时，产生的数值在用于分析的分光光度计的噪声水平的约+/- 200％之内。[II]通过使用抑制剂获得最佳结果其提供选自ClO 3 - ，ClO 4 - ，SCN-或I-的阴离子。

4. 发明授权

US5429930A Kinetic enzyme assay for determining the CO.sub.2 content of body fluids using PEP carboxylase with inhibitor 失效
标题翻译：动力学酶法测定使用PEP羧化酶与抑制剂的体液二氧化碳含量
公开(公告)号：US5429930A
公开(公告)日：1995-07-04
申请号：US119586
申请日：1993-09-13
申请人： Bryce A. Cunningham , George F. Johnson , Rubio R. Punzalan
发明人： Bryce A. Cunningham , George F. Johnson , Rubio R. Punzalan
IPC分类号： C12Q1/32 , C12Q1/48 , C12Q1/527 , C12N9/10 , C12N9/88
CPC分类号： C12Q1/48 , C12Q1/32 , C12Q1/527
摘要： An improved kinetic assay is provided for spectrophotometrically determining the dissolved carbon dioxide (CO.sub.2) content of a body fluid (e.g., blood, plasma or serum), wherein at about pH 8.0 the CO.sub.2 is present substantially as bicarbonate ion (HCO.sub.3.sup.-). The assay sample is first subjected to a coupled reaction mixture containing phosphoenolpyruvate (PEP) and phosphoenolpyruvate carboxylase (PEPC) which enzymatically catalyzes conversion of HCO.sub.3.sup.- to oxaloacetate (OA). The OA produced is subjected to a second coupled reaction mixture containing nicotinamide adenine dinucleotide (NADH) and malate dehydrogenase (MDH) which thereby reduces the OA to malate and oxidizes the NADH to NAD.sup.+. The CO.sub.2 level in the body fluid sample may indirectly be determined by spectrophotometrically measuring the change in NADH concentration. According to the invention, an amount of an inhibitor is added to the reaction mixture which renders the reaction kinetics of the system essentially first order over the entire bicarbonate concentration range of interest. A useful inhibitor substantially satisfies a model represented by the monoexponential equationA.sub.t =(A.sub.o -A.sub..infin.)e.sup.-kt +A.sub..infin. [I]A sufficient quantity of the inhibitor is present to substantially cause the coupled reactions to follow the model equation [I] and yield a number which is within about .+-.200% of the noise level of the spectrophotometer used for the assay when each absorbance value is applied to the equation ##EQU1## Best results have been obtained through use of an inhibitor which provides an anion selected from the group consisting of ClO.sub.3.sup.-, ClO.sub.4.sup.-, SCN.sup.-, or I.sup.-.
摘要翻译：提供改进的动力学测定用于分光光度测定体液（例如血液，血浆或血清）的溶解二氧化碳（CO 2）含量，其中在约pH8.0时，CO 2基本上以碳酸氢根离子（HCO 3 - ）存在。首先对测定样品进行含有磷酸烯醇丙酮酸（PEP）和磷酸烯醇丙酮酸羧化酶（PEPC）的偶联反应混合物，其中酶促催化HCO3-转化为草酰乙酸（OA）。生成的OA经受含有烟酰胺腺嘌呤二核苷酸（NADH）和苹果酸脱氢酶（MDH）的第二偶联反应混合物，由此将OA还原为苹果酸，并将NADH氧化成NAD +。通过分光光度法测量体液样品中的二氧化碳水平可以间接测定NADH浓度的变化。根据本发明，将一定量的抑制剂加入到反应混合物中，使得系统的反应动力学在感兴趣的整个碳酸氢盐浓度范围内基本上是一级。有用的抑制剂基本上满足由单指数方程表示的模型At =（Ao-A INFINITY）e-kt + A INFINITY [I]存在足够量的抑制剂以基本上使偶联反应遵循模型方程[I ]，并且当将每个吸光度值应用于方程式时，产生的数值在用于分析的分光光度计的噪声水平的约+/- 200％之内。[II]通过使用抑制剂获得最佳结果其提供选自ClO 3 - ，ClO 4 - ，SCN-或I-的阴离子。

5. 发明申请

US20100323920A1 ALLOGENEIC STEM CELL BANK 审中-公开
标题翻译：全息干细胞库
公开(公告)号：US20100323920A1
公开(公告)日：2010-12-23
申请号：US12762118
申请日：2010-04-16
申请人： Robert Chow , Lawrence D. Petz , Rubio R. Punzalan , Denis O. Rodgerson
发明人： Robert Chow , Lawrence D. Petz , Rubio R. Punzalan , Denis O. Rodgerson
IPC分类号： C40B40/02
CPC分类号： A61K35/50 , A61K35/16 , A61K35/28 , G16H50/80
摘要： This invention provides methods for supplying a therapy for individuals exposed to radiation following a nuclear event, through the prospective establishment of an undesignated allogeneic stem cell bank with prospective HLA typing of healthy potential recipients.
摘要翻译：本发明提供了通过预期建立具有健康潜在接受者的预期HLA分型的未指定的同种异体干细胞库来为核事件后暴露于辐射的个体提供治疗的方法。

6. 发明申请

US20100221230A1 Elective Collection and Banking of Autologous Peripheral Blood Stem Cells 审中-公开
标题翻译：自体外周血干细胞的选择性收集和银行
公开(公告)号：US20100221230A1
公开(公告)日：2010-09-02
申请号：US12775606
申请日：2010-05-07
申请人： Thomas Gordon HIROSE , Simon Sun-man Lam , Rubio R. Punzalan , Denis O. Rodgerson
发明人： Thomas Gordon HIROSE , Simon Sun-man Lam , Rubio R. Punzalan , Denis O. Rodgerson
IPC分类号： A61K35/12 , C12N5/074 , A61P43/00 , A61P35/00
CPC分类号： C12N5/0607 , A61K35/12 , A61K2035/124 , C12N5/0647
摘要： An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or “pre-disease” state, for future distribution for his or her healthcare needs. The process includes methods of collection, processing, preservation and distribution of adult (including pediatric) peripheral blood stem cells during non-diseased state. The stem cells collected will contain adequate dosage amounts, for one or more transplantations immediately when needed by the individual for future healthcare treatments. The collected adult or non-neonate child peripheral blood stem cells can be aliquoted into defined dosage fractions before cryopreservation so that cells can be withdrawn from storage without the necessity of thawing all of the collected cells.
摘要翻译：使用个人自己的外周血干细胞作为个人未来医疗保健用途的选择性医疗保险模式。当他或她处于健康或“疾病前”状态时，个人可以选择收集，加工和保存自己的干细胞，以便将来分配他或她的医疗保健需求。该过程包括在非疾病状态下收集，处理，保存和分配成人（包括小儿）外周血干细胞的方法。收集的干细胞将含有足够的剂量，用于个体为将来的保健治疗需要时立即进行一次或多次移植。收集的成年或非新生儿儿童外周血干细胞可以在冷冻保存之前等分到确定的剂量组分中，使得细胞可以从储存中取出，而不需要解冻所有收集的细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式